Johnson & Johnson (JNJ) DIvidends Date & History

Key Takeaways

• Johnson & Johnson (JNJ) offers a current dividend yield of approximately 2.2%, paid quarterly at $1.30 per share, totaling $5.20 annually.
• The company boasts a remarkable 64-year streak of consecutive dividend increases, underscoring its reliability as a dividend aristocrat.
• Payout ratio stands at around 47%, indicating strong sustainability backed by robust earnings and free cash flow.
• Free cash flow of about $20 billion in recent years comfortably covers dividend payments, supporting ongoing growth.
• Compared to pharma peers, JNJ's yield is solid but trails higher-yield names like PFE (6.3%).
• Ideal for conservative dividend growth investors seeking stability over high yield.

Dividend Overview

Johnson & Johnson (JNJ), a global healthcare leader in pharmaceuticals, medical devices, and consumer health, maintains a consistent quarterly dividend policy. The current quarterly dividend is $1.30 per share, equating to an annual payout of $5.20 and a yield of approximately 2.2% based on recent stock prices around $240. The next ex-dividend date was February 24, 2026, with payment on March 10, 2026. This positions JNJ as a classic dividend growth stock rather than a high-yield play, appealing to investors prioritizing long-term income reliability over immediate high returns. With over 60 years of uninterrupted payments and annual raises, the dividend reflects the company's resilient business model and commitment to shareholders.

Dividend History and Growth

Johnson & Johnson has an exemplary dividend history, with 64 consecutive years of increases as of 2026, earning its status as a Dividend King. Recent hikes include a jump from $1.24 to $1.30 per share in early 2025, representing about 4.8% growth. Over the past year, dividend growth was around 4.7%, with five-year averages near 5.25%. The company has never cut its dividend, even through economic downturns, supported by diversified revenue streams. This long-term strategy prioritizes steady, predictable growth aligned with earnings expansion, as detailed in its investor relations disclosures.

Dividend Sustainability and Payout Ratio

JNJ's dividend sustainability is robust, with a payout ratio of approximately 47% of earnings, leaving ample room for reinvestment and resilience. Free cash flow (FCF), a key metric of cash after capital expenditures, reached about $20 billion in 2025, easily covering the roughly $12.5 billion annual dividend outlay—around 60-64% of FCF. A low debt-to-equity ratio of 0.48 and net debt coverage by FCF further bolster stability. Earnings growth projections and a conservative payout affirm the dividend's safety for the foreseeable future.

Dividend Compared to Industry Peers

In the pharmaceuticals and healthcare sector, where the average yield hovers around 2-3%, JNJ's 2.2% yield is competitive yet moderate. Peers like PFE offer higher yields near 6.3%, driven by post-COVID dynamics, while MRK (2.8%) and ABT (2.5%) are similar. Consumer stalwart PG yields about 2.9%. JNJ stands out for its unmatched growth streak and lower payout ratio, prioritizing quality over yield in a sector prone to patent cliffs and R&D volatility.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to streamline your research today.

Is This Stock Attractive for Dividend Investors?

Johnson & Johnson (JNJ) appeals to conservative dividend growth investors who value longevity and stability over sky-high yields. Its 64-year increase streak and modest 2.2% yield make it suitable for long-term holders building portfolios resilient to market cycles. Income seekers may find it less compelling compared to ultra-high yielders like PFE, but the low payout ratio and FCF coverage offer peace of mind amid healthcare sector uncertainties like drug pricing pressures or litigation. For retirees or risk-averse investors prioritizing capital preservation alongside modest income, JNJ's diversified operations—spanning innovative medicine and medtech—provide a defensive edge. Balanced against peers, it suits those favoring quality and sustainability in dividend investing strategies.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations